In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones

Several 5-benzyl-2,4-thiazolidinediones ( 5– 7) were synthesised and tested as in vitro aldose reductase (ALR2) inhibitors. Most of them, particularly N-unsubstituted 5-benzyl-2,4-thiazolidinediones 5 and (5-benzyl-2,4-dioxothiazolidin-3-yl)acetic acids 7, displayed moderate to high inhibitory activ...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry Vol. 14; no. 2; pp. 567 - 574
Main Authors: Rakowitz, Dietmar, Maccari, Rosanna, Ottanà, Rosaria, Vigorita, Maria Gabriella
Format: Journal Article
Language:English
Published: Oxford Elsevier Ltd 15-01-2006
Elsevier Science
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several 5-benzyl-2,4-thiazolidinediones ( 5– 7) were synthesised and tested as in vitro aldose reductase (ALR2) inhibitors. Most of them, particularly N-unsubstituted 5-benzyl-2,4-thiazolidinediones 5 and (5-benzyl-2,4-dioxothiazolidin-3-yl)acetic acids 7, displayed moderate to high inhibitory activity levels. In detail, the insertion of an acetic chain on N-3 significantly enhanced ALR2 inhibitory potency, leading to acids 7 which proved to be the most effective among the tested compounds. In addition, in N-unsubstituted derivatives 5 the presence of an additional aromatic ring on the 5-benzyl moiety was generally beneficial. In fact, the ALR2 inhibition results of compounds 5– 7, compared to those of the previously assayed corresponding 5-arylidene-2,4-thiazolidinediones, indicated that N-unsubstituted derivatives 5b, c and d, which bore an additional aromatic group in the para position of the 5-benzyl residue, were significantly more effective than their 5-arylidene counterparts; in all other cases, the saturation of the exocyclic double bond C C in 5 brought about a moderate decrease in activity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2005.08.056